Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Parma – page 6

219 clinical trials in Parma, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Parma at a glance
219
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

219 trials in Parma

Open in trial search

Metastatic renal cell carcinoma

Recruiting

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Consorzio Oncotech

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Non-Hodgkin's lymphoma

Recruiting

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Factor VIII deficiency

Recruiting

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Colorectal cancer stage II+1

Recruiting

Study on Colon Cancer Treatment Using Disodium Levofolinate and Drug Combination for Patients with Operable Stage III and High-Risk Stage II Colon Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Factor VIII deficiency+3

Recruiting

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Plasma cell myeloma

Recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Chronic lymphocytic leukaemia

Recruiting

Study of venetoclax, obinutuzumab and zanubrutinib combination therapy in young patients with high-risk Chronic Lymphocytic Leukemia and residual disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Myocarditis

Recruiting

Study on the Safety and Effectiveness of Methylprednisolone Sodium Succinate and Sodium Chloride for Patients with Severe Cardiac Inflammation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

Small cell lung cancer+1

Recruiting

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 764532
  • Sponsor:Boehringer Ingelheim International GmbH

Non-small cell lung cancer

Recruiting

Study on the Safety and Effectiveness of Zipalertinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Specific EGFR Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Digoxin
  • Sponsor:Taiho Oncology Inc.

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Parma

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, lung cancer, and breast cancer treatments. Investigations include innovative immunotherapy approaches and targeted therapies for various cancer types.

  • Novel therapies for NSCLC patients
  • Triple-negative breast cancer treatments
  • Multiple myeloma management strategies

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Respiratory Medicine

Studies examining treatments for respiratory syncytial virus (RSV) infections in high-risk populations. Advanced research into preventive therapies and management strategies.

  • RSV prevention in infants
  • Respiratory support strategies
  • Critical care ventilation protocols

Focus on developing protective measures for vulnerable patient populations.

03 Transplant Medicine

Clinical trials evaluating new approaches to kidney transplantation and prevention of complications. Research on reducing delayed graft function and improving transplant outcomes.

  • Post-transplant care optimization
  • Graft function improvement
  • Novel immunosuppressive strategies

Emphasis on enhancing long-term transplant success rates.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.